Recruiting
Phase 1

DC/MM Fusion Vaccine & Elranatamab

Sponsor:

David Avigan

Code:

NCT06799026

Conditions

Multiple Myeloma

Relapse Multiple Myeloma

Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elranatamab

GM-CSF

DC/MM Fusion Vaccine

Study Details

Brief summary:

This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM).

The names of the study drugs and vaccine involved in this study are:

  • DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells)
  • Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor)
  • Elranatamab (a type of T-cell engager antibody)

Conditions

Multiple Myeloma

Relapse Multiple Myeloma

Refractory Multiple Myeloma

Study ID

NCT06799026

Start date

Jan 31, 2025

Status verified date

May, 2026

Completion date

Sep 1, 2030

Anticipated

Primary completion date

Sep 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria for Tumor Collection:

  • Participants must have an established diagnosis of multiple myeloma
  • Participant must have multiple myeloma and have relapsed following or are refractory to proteasome inhibitors, IMiDs and anti-CD38 mAb therapy
  • Participants must have at least 3 prior lines of therapy
  • Participants must be ≥18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Participants must have > 20% plasma cells in the bone marrow core or aspirate differential <30 days prior to enrollment.
  • ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
  • Participants must have adequate organ function as defined below:

  • Total bilirubin ≤1.5 x institutional upper limit of normal
  • AST ≤ 3 x institutional upper limit of normal
  • ALT ≤ 3 x institutional upper limit of normal
  • Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal
  • The effects of DC/MM fusion vaccine on the developing human fetus are unknown. For this reason, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier methods of birth control or abstinence) prior to study enrollment and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of treatment.
  • Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria for Tumor Collection:

  • Patients who are receiving any other investigational agents.
  • Patients with purely non-secretory MM \[absence of a monoclonal protein (M protein) in serum as measured by electrophoresis and immunofixation and the absence of Bence- Jones protein in the urine defined by use of conventional electrophoresis and immunofixation techniques and the absence of involved serum free light chain >100 mg/L\]. Patients with light chain MM detected in the serum by free light chain assay are eligible.
  • Patients with Plasma Cell Leukemia
  • Because of compromised cellular immunity, patients who have a known human immunodeficiency virus (HIV), active hepatitis C virus (HCV) or active hepatitis B virus (HBV).
  • Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure (see Appendix H), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening will be documented by the investigator as not medically relevant.
  • Active and clinically significant autoimmune or inflammatory disorder requiring active treatment
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances. Note: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: non- invasive cancer (such as, any in situ cancers) and basal cell or squamous cell carcinoma of the skin.
  • Female patients who are pregnant (positive β-HCG) or breastfeeding
  • Prior organ transplant requiring immunosuppressive therapy.
  • Patients who previously received PD-1 antibody and have experienced toxicities resulting in treatment discontinuation.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • History of GBS or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.

Eligibility Criteria Prior to Vaccination with DC/MM fusions

  • Resolution of all elranatamab related ≥ grade 3 or higher toxicities to grade 1 or baseline. Isolated laboratory abnormalities that are not considered to be clinically significant are not exclusionary.
  • Successful production of at least 2 vaccines with a minimum of 1 x 106 fusion cells per vaccine
  • Absence of disease progression following 2 cycles of elranatamab therapy
  • ECOG performance status ≤ 2

Participants must have adequate organ function as defined below:

  • Total bilirubin ≤ 1.5 x institutional upper limit of normal
  • AST ≤ 3 x institutional upper limit of normal
  • ALT ≤ 3 x institutional upper limit of normal
  • ANC > 1K/uL; Platelets > 50 K/uL without transfusional support
  • Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Elranatamab + DC/MM Vaccine + GM-CSF

  • Baseline visit and assessments
  • Leukapheresis
  • Cycle 1 (28-day cycle):

--Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily
  • Cycle 2 (28-day cycle):

--Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily
  • Cycles 3 through 5 (28-day cycles):

  • Bone marrow biopsy/aspiration prior to first DC/MM fusion vaccine
  • Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily
  • Day 8: Predetermined doses of DC/MM fusion vaccine 1x daily and GM-CSF 1x daily (GM-CSF for days 9 through 11 are self-administered)
  • Cycle 6 (28-day cycle):

  • Bone marrow biopsy/aspiration on Cycles 6, 9, and 12
  • Days 1, 8, 15, and 22: Predetermined dose of Elranatamab 1x daily
  • Cycle 7 through 12 (28-day cycles):

  • Cycle 7 Day 1 only: Bone marrow biopsy/aspiration
  • Days 1 and 15: Predetermined dose of Elranatamab 1x daily
  • After end of treatment, bone marrow biopsy/aspiration at months 1, 3, and 6
  • 6 month follow up visit
  • Long term follow up 5 years

Interventions

Elranatamab

Bispecific T-cell engager antibody, 1.9 and 1.1 mL vials, via subcutaneous (under the skin) injection per protocol.

GM-CSF

Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous (under the skin) injection per protocol.

DC/MM Fusion Vaccine

Dendritic Cell and tumor fusion vaccine, via subcutaneous (under the skin) injection per protocol.

Primary outcome measure

  • Administration of DC/MM Vaccine [ Time Frame: 1 Year ]
  • Grade 3-4 Non-hematologic Rate [ Time Frame: 1 Year ]
  • Grade 3-4 hematologic Rate [ Time Frame: 1 Year ]

Central Contacts and Locations

Central contacts

David Avigan, MD

617-667-9920davigan@bidmc.harvard.edu

Emma Logan, MSN

617-667-9920eklogan@bidmc.harvard.edu

Locations

Beth Israel Deaconess Medical Center

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

David Avigan, MD

617-667-9920davigan@bidmc.harvard.edu

Emma Logan, MSN

617667-9920eklogan@bidmc.harvard.edu

Principal Investigator:

David Avigan, MD

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

David Avigan, MD

617-667-9920davigan@bidmc.harvard.edu

Principal Investigator:

David Avigan, MD

More Information

Sponsor

David Avigan

Last update posted

May 7, 2026

Last verified

May, 2026

Keywords

  • MM
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by David Avigan on 2026-05-07.